Pathobiology of Japanese encephalitis virus infection.

Adaptive immunity Antivirals Autophagy Flavivirus Innate immunity Japanese encephalitis virus Neuroinflammation Vaccines

Journal

Molecular aspects of medicine
ISSN: 1872-9452
Titre abrégé: Mol Aspects Med
Pays: England
ID NLM: 7603128

Informations de publication

Date de publication:
Oct 2021
Historique:
received: 12 02 2021
revised: 13 07 2021
accepted: 13 07 2021
pubmed: 19 7 2021
medline: 30 12 2021
entrez: 18 7 2021
Statut: ppublish

Résumé

Japanese encephalitis virus (JEV) is a flavivirus, spread by the bite of carrier Culex mosquitoes. The subsequent disease caused is Japanese encephalitis (JE), which is the leading global cause of virus-induced encephalitis. The disease is predominant in the entire Asia-Pacific region with the potential of global spread. JEV is highly neuroinvasive with symptoms ranging from mild fever to severe encephalitis and death. One-third of JE infections are fatal, and half of the survivors develop permanent neurological sequelae. Disease prognosis is determined by a series of complex and intertwined signaling events dictated both by the virus and the host. All flaviviruses, including JEV replicate in close association with ER derived membranes by channelizing the protein and lipid components of the ER. This leads to activation of acute stress responses in the infected cell-oxidative stress, ER stress, and autophagy. The host innate immune and inflammatory responses also enter the fray, the components of which are inextricably linked to the cellular stress responses. These are especially crucial in the periphery for dendritic cell maturation and establishment of adaptive immunity. The pathogenesis of JEV is a combination of direct virus induced neuronal cell death and an uncontrolled neuroinflammatory response. Here we provide a comprehensive review of the JEV life cycle and how the cellular stress responses dictate the pathobiology and resulting immune response. We also deliberate on how modulation of these stress pathways could be a potential strategy to develop therapeutic interventions, and define the persisting challenges.

Identifiants

pubmed: 34274157
pii: S0098-2997(21)00054-6
doi: 10.1016/j.mam.2021.100994
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

100994

Informations de copyright

Copyright © 2021. Published by Elsevier Ltd.

Auteurs

Kiran Bala Sharma (KB)

Virology Research Group, Regional Centre for Biotechnology, NCR Biotech Science Cluster, Faridabad, India.

Sudhanshu Vrati (S)

Virology Research Group, Regional Centre for Biotechnology, NCR Biotech Science Cluster, Faridabad, India. Electronic address: vrati@rcb.res.in.

Manjula Kalia (M)

Virology Research Group, Regional Centre for Biotechnology, NCR Biotech Science Cluster, Faridabad, India. Electronic address: manjula@rcb.res.in.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH